References

  1. Adamson S (1985) Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. San Francisco: Four Trees Publications.
  2. Alting Von Geusau N, Stalenhoef, P, Huizinga M, Snel J, Ridderinkhof KR (2004) Impaired executive function in male MDMA (Ecstasy) users.
  3. Psychopharmacology (Berl) Published on-line March 18, 2004. DOI: 10.1007/s00213-004-1832-8.
  4. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, Rodes J (1998)
  5. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 29: 394-397.
  6. Auer J, Berent R, Weber T, Lassnig E, Eber B (2002) Subarachnoid haemorrhage with "Ecstasy" abuse in a young adult. Neurol Sci 23: 199-201.
  7. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE (2003) Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in recreational users. Clin Neuropsychol 17; 446-459.
  8. Badaoui R, El Kettani C, Fikri M, Ouendo M, Canova-Bartoli P, Ossart M (2002) Spontaneous cervical and mediastinal air emphysema after ecstasy abuse. Anesth Analg 95: 1123.
  9. Baggott M (2002) Preventing problems in ecstasy users; Reduce use to reduce harm. J Psychoactive Drugs 34: 145-162.
  10. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J Chemical analysis of ecstasy pills (2000) JAMA 284: 2190.
  11. Baggott M, Mendelson J (2001) Does MDMA cause brain damage? In Holland J (Ed). Ecstasy, A Complete Guide. Rochester VT: Inner Tradition, 110-145.\
  12. Baggott M, Jerome L, Stuart R (2001) 3,4-Methylenedioxymethamphetamine (MDMA) A Review of the English-Language Scientific and Medical Literature. Published on-line: http://www.maps.org/research/mdma/protocol/litreview.html.
  13. Ball KT, Budreau D, Rebec GV. (2003) Acute effects of 3,4- methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res 994:203-215.
  14. Beck A, Weissman A, Lester D, Trexler L. (1974) The measurement of pessimism: the Beck Hopelessness Scale. J Consult Clin Psychol 42:861­865.
  15. Ben-Abraham R, Szold O, Rudick V, Weinbroum AA. (2003) 'Ecstasy' intoxication: life- threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med. 2003 Dec;10(4):309-313.
  16. Beveridge TJ, Mechan AO, Sprakes M, Pei Q, Zetterstrom TS, Green AR, Elliott JM (2004) Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain. Psychopharmacology (Berl). 173:346-352.
  17. Bhattachary S, Powell JH (2001) Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': Evidence for cognitive impairment. Psychological Med 31: 647-658.
  18. Bogen IL, Haug KH, Myhre O, Fonnum F (2003) Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43: 393-400.
  19. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51: 1532-1537.
  20. Bond AJ, Verheyden SL, Wingrove J, Curran HV. (2004) Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology (Berl) 171:331-339.
  21. Bouso JC (2001) Using MDMA in the treatment of posttraumatic stress disorder. In Holland J (Ed). Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 248- 260.
  22. Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD, Ali SF, Frederick DL, Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24: 379-390.
  23. Brazier WJ, Dhariwal DK, Patton DW, Bishop K (2003) Ecstasy related periodontitis and mucosal ulceration - a case report. Br Dent J 194: 197-199.
  24. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. (2003) 3,4- Methylenedioxymethamphetamine (Ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
  25. Brookhuis KA, De Waard D, Samyn N. (2004) Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology (Berl) 173: 440-445.
  26. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-84.
  27. Bull EJ, Hutson PH, Fone KC. (2004) Decreased social behaviour following 3,4- methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5- HT(2A) receptor responsivity. Neuropharmacology. 46:202-210.
  28. Caballero F, Lopez-Navidad A, Cotorruelo J, Txoperena G (2002) Ecstasy-induced brain death and acute hepatocellular failure: multiorgan donor and liver transplantation. Transplantation 74: 532-537.
  29. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466.
  30. Carvalho M, Carvalho F, Bastos ML (2001) Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4- methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch Toxicol 74: 789- 793.
  31. Carvalho M, Carvalho F, Remiao F, de Lourdes Pereira M, Pires-Das-Neves R, de Lourdes Bastos M (2002). Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76: 166-172.
  32. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, Monks TJ,
  33. Carvalho F, Bastos ML. (2003) Hepatotoxicity of 3,4- methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78:16-24.
  34. Chang L, Ernst T, Grob CS, Poland RE (1999). Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users. J Magn Reson Imaging 10: 521-526.
  35. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98: 15-28.
  36. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS. (2003) MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 173:318-325. Epub 2004 Mar 17.
  37. Cohen RS (1995) Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 19: 1137-1145.
  38. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531- 1536.
  39. Cole JC, Sumnall HR (2003a) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98: 35-58.
  40. Cole JC, Sumnall HR (2003b) The pre-clinical behavioural pharmacology of 3,4- methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27:199- 217.
  41. Cole JC, Sumnall HR, O'Shea E, Marsden CA (2003) Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology (Berl) 166:383-390.
  42. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS. (2003) Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482:339-341.
  43. Cottler L, Womack SB, Compton WM, Ben-Abdallah A (2001). Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Human Psychopharmacology, Clinical and Experimental, 16, 599-606.
  44. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, Haga E, Vimal RL, Lukas SE, Renshaw PF. (2003). Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend. 72:225-235.
  45. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001) The relative contribution of ecstasy and cannabis to cognitive impairment. Psychopharmacol 153: 373-379.
  46. Curran HV, Verheyden SL (2003) Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology 169: 91-103.
  47. Curran HV, Rees H, Hoare T, Hoshi R, Bond A. (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology (Berl) 173:425-433. Epub 2004 Jan 20.
  48. Dafters RI, Biello SM. (2003) The effect of 3,4-methylenedioxymethamphetamine ('Ecstasy') on serotonergic regulation of the mammalian circadian clock mechanism in rats: the role of dopamine and hyperthermia. Neurosci Lett. 350:117-121.
  49. Dafters RI, Hoshi R, Talbot AC. (2004) Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacology (Berl) 173:405-410.
  50. Davison D, Parrott AC (1997) Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects. Human Psychopharmacology Clinical & Experimental 12: 221-226.
  51. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E. (2001) Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol. 16:627-633.
  52. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis-Mayfrank E. (2003A) Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study.Brain Res Cogn Brain Res. 16(:479-487.
  53. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E.(2003B) Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport 14:1983-1987.
  54. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. (2004) Self- reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl) 173:398- 404.
  55. Davidoff R, McTiernan A, Constantine G, Davis KD, Balady GJ, Mendes LA, Rudolph RE, Bowen DJ. (2001) Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 161:1429-1436.
  56. De la Torre R (2004) Personal communication to L Jerome, March 5, 2004.
  57. De la Torre R, Farre M, Roset PN, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E,
  58. Pizarro N, Segura J, Cami J. (2000) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-237.
  59. De Win MM, Reneman L, Reitsma JB, Den Heeten GJ, Booij J, Van Den Brink W. (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 173:376-382.
  60. Delgado JH, Caruso MJ, Waksman JC, Honigman B, Stillman D. (2004) Acute, transient urinary retention from combined ecstasy and methamphetamine use. J Emerg Med. 2004 Feb;26(2):173-175.
  61. Doblin R (2002) Letter from Rick Doblin. MAPS Bulletin 12(3):3-4.
  62. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340.
  63. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH (2003) Pharmacological characterization of the effects of 3,4- methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166:202-211.
  64. Fantegrossi WE, Kiessel CL, Leach PT, Martin CV, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. (2004A) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) 173:270-277.
  65. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G. (2004B) Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys. Neuropsychopharmacology. Published electronically Feb 16 2004
  66. Farre M, De La Torre R, O Mathuna B, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J. (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 173:364-375.
  67. Ferrucci M, Gesi M, Lenzi P, Soldani P, Ruffoli R, Pellegrini A, Ruggieri S, Paparelli A, Fornai F (2002) Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls. Neurol Sci 23 Suppl 2: S75-S76.
  68. Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Menge M, Schulte Am Esch J. (2003) Induction of malignant hyperthermia in susceptible swine by 3,4- methylenedioxymethamphetamine ("ecstasy"). Anesthesiology 99:1132-1136.
  69. Finsterer J, Stollberger C, Steger C, Kroiss A (2003) Long lasting impaired cerebral blood flow after ecstasy intoxication. Psychiatry Clin Neurosci 57: 221-225.
  70. Fone KCF, Beckett SRC, Topham IA, Swettenham J, Ball M, Maddocks L (2002). Long- term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl), 159: 437-444.
  71. Fornai F, Lazzeri G, Lenzi P, Gesi M, Ferrucci M, Soldani P, Pellegrini A, Capobianco L, De Blasi A, Ruggieri S, Paparelli A. (2003) Amphetamines induce ubiquitin- positive inclusions within striatal cells. Neurol Sci 24:182-183.
  72. Fornai F, Lenzi P, Frenzilli G, Gesi M, Ferrucci M, Lazzeri G, Biagioni F, Nigro M, Falleni A, Giusiani M, Pellegrini A, Blandini F, Ruggieri S, Paparelli A. (2004) DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berl) 173:353-363.
  73. Fox HC, Toplis AS, Turner JJD, Parrott AC (2001A). Auditory verbal learning in drug- free polydrug users. Human Psychopharmacol Clin Exp, 16: 613-618.
  74. Fox, HC, Parrott, AC and Turner, JJD (2001B). Ecstasy use; Cognitive deficits related to dosage rather than to self-reported problematic use of the drug. J of Psychopharmacology, 15: 273-28.
  75. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ. (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl) 162:203-214.
  76. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX (2001) Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 14: 152-165.
  77. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000A) 3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388-395.
  78. Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000b) Mood state and brain electric activity in ecstasy users. Neuroreport 11: 157-162.
  79. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F. (2000) Long-lasting effects of (+/-)3,4- methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47: 127-136.
  80. Gerra G, Zaimovic A, Ampollini R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F. (2001) Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates. J Subst Abuse 13: 471-491.
  81. Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R, Laviola G, Macchia T, Brambilla F (2002) Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans. Behav Brain Res 134: 403- 410.
  82. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari R, Brambilla F, Molina E. (2003) Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 120:115-124.
  83. Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF (1999) MDMA study (Letter to the Editor). Neuropsychopharmacol 21: 597.
  84. Gijsman HJ, Van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, Hessing TJ, Cohen AF (2002) Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. Hum Psychopharmacology 17: 83-89.
  85. Gordon J, Barnes NM (2003) Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol 24:438-443.
  86. Gore SM. (1999) Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 354:1265-1266.
  87. Gouzoulis-Mayfrank, E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68: 719-725.
  88. Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J (2002). Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: Is it ecstasy or cannabis? Biological Psychiatry, 51, 766-769.
  89. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hansen G, Daumann J (2003) Memory impairments suggest hippocampal dysfunction in abstinent Ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27: 819-827.
  90. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI. (2003A) Effect of ambient temperature and a prior neurotoxic dose of 3,4- methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology (Berl) 173: 264-269.
  91. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. (2003B) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
  92. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21:121-124.
  93. Greer G, Tolbert RA (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327.
  94. Greer GR, Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30: 371-379.
  95. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4- methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73: 103-107.
  96. Grob CS, Poland RE, Boone KB (Unpublished) Psychological, physiological and neuroendocrine effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in healthy humans. Data presented in Investigators' Brochure.
  97. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446: 89-96.
  98. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JH, Yurgelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Dependence. In press, Electronically published May, 2004. DOI: DOI: 0.1016/j.drugalcdep.2004.02.008.
  99. Hanson KL and Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229-246.
  100. Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002). Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl) 162: 396-405.
  101. Heekeren K, Daumann J, Geyer MA, Gouzoulis-Mayfrank E. (2004) Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. Psychopharmacology (Berl) 173:418-424.
  102. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J (2001). Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Human Psychopharmacol, 16: 607-612.
  103. Henry JA, Rella JG (2001) Medical risks associated with MDMA use. In Holland J (Ed). Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 71-86.
  104. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4- methylenedioxymethamphetamine ("ecstasy"). Lancet 340: 384-387.
  105. Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-244.
  106. Holland J (Ed). (2001). Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester VT: Inner Traditions. Inman DS, Greene D (2003) 'The agony and the ecstasy': acute urinary retention after MDMA abuse. BJU Int 91: 123.
  107. Itzhak Y, Ali SF, Achat CN, Anderson KL (2003) Relevance of MDMA ("ecstasy")- induced neurotoxicity to long-lasting psychomotor stimulation in mice. Psychopharmacology 166: 241-248.
  108. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173:383- 390. Epub 2003 Nov 28.
  109. Jansen KL (1999. Ecstasy (MDMA) dependence Drug Alcohol Depend 53:121-124.
  110. Jerome L, Baggott M (2003) MAPS' MDMA Investigator's Brochure Update #1 A Review of Research in Humans and Non-Human Animals. Published on-line at http://www.maps.org/research/mdma/protocol/litupdate1.pdf/.
  111. Jerome L, Doblin R, Mithoefer MC (2004, In Press) Ecstasy use-Parkinson's link tenuous. Mov Disord.
  112. Johnson EA, O'Callaghan JP, Miller DB. (2004) Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berl). 2004 May;173(3-4):278-286.
  113. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137: 963-970.
  114. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71 845­855.
  115. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user Neurology 55:294-296.
  116. Kish SJ. (2003) What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? Mov Disord.18:1219-1223.
  117. Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. (2003A) Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol 25: 509-517.
  118. Koprich JB, Campbell NG, Lipton JW. (2003B) Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Res Dev Brain Res Dec 147:177-182. Kuniyoshi SM Jankovic J. (2003) MDMA and Parkinsonism. N Engl J Med 349: 96-97.
  119. Kwon C, Zaritsky A, Dharnidharka VR (2003) Transient proximal tubular renal injury following Ecstasy ingestion. Pediatr Nephrol 18: 820-822. Lai TI, Hwang JJ, Fang CC, Chen WJ. (2003) Methylene 3, 4 dioxymethamphetamine- induced acute myocardial infarction. Ann Emerg Med 42:759-762.
  120. Lamers CTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17(4); 379-387.
  121. Lamers CTJ (2003) Personal communication to L Jerome, March 19 and March 20, 2003.
  122. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double- blind, placebo-controlled trial. Ann Intern Med 133: 969-973.
  123. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68:195-207.
  124. Lieberman JA, Aghajanian GK (1999) Caveat emptor: Researcher beware. Neuropsychopharmacol 21: 471-473.
  125. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000A) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 22: 513-521.
  126. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000B) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacol 23: 396-404.
  127. Liechti ME, Vollenweider FX (2000A) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10: 289-295.
  128. Liechti ME, Vollenweider FX (2000B) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4- methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14: 269-274.
  129. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacol 154: 161-168.
  130. Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4- \methylenedioxymethamphetamine use. J Nerv Ment Dis 180: 345-52; discussion 353-354.
  131. Logan BK, Couper FJ (2001). 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci 46: 1426-1433.
  132. Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans. Biol Psychiatry 53 (Suppl); 205S. Data presented at the 58th Annual Conference of the Society for Biological Psychiatry, San Francisco, CA.
  133. Madhok A, Boxer R, Chowdhury D. (2003) Atrial fibrillation in an adolescent--the agony of ecstasy. Pediatr Emerg Care 19:348-349.
  134. Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology (Berl) 144: 67-76.
  135. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136- 145.
  136. Masi G, Muci M, Floriani C (2002). Acute catatonia after a single dose of ecstasy. J Am Acad Child Adolesc Psychiatry 41: 892.
  137. McCann UD, Ricaurte G (2001) Caveat Emptor: Editors Beware. Neuropsychopharmacology 24: 333-334.
  138. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) 143: 417-425.
  139. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
  140. McCardle, K, Luebbers, S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (Ecstasy) use, cognition and mood. Psychopharmacology (Berl) Published on- line April 18, 2004. DOI: 10.1007/s00213-004-1791-0.
  141. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999) Congenital anomalies after prenatal ecstasy exposure. Lancet 354: 1441-1442
  142. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE (2003) Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 168:465-474.
  143. McGregor IS, Clemens KJ, Van Der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003) Increased Anxiety 3 Months after Brief Exposure to MDMA ('Ecstasy') in Rats: Association with Altered 5-HT Transporter and Receptor Density. Neuropsychopharmacology 28:1472-1484.
  144. Michael JC, Pak J, Pulido J, de Venecia G. (2003) Central serous chorioretinopathy associated with administration of sympathomimetic agents.Am J Ophthalmol. 2003 Jul;136(1):182-185.
  145. Mills EM, Banks ML, Sprague JE, Finkel T. (2003) Pharmacology: uncoupling the agony from ecstasy. Nature 426: 403-404.
  146. Mithoefer M (2004) MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder; a fourth update on the approval process and first report on study progress. MAPS Bulletin 14(1): 3-4.
  147. Mithoefer M, Jerome L, Doblin R (2003) MDMA ("Ecstasy") and neurotoxicity. Science 300:1504.
  148. Montiel-Duarte C, Varela-Rey M, Oses-Prieto J, Lopez-Zabalza M, Beitia G, Cenarruzabeitia E, Iraburu M (2002) 3,4-Methylenedioxymethamphetamine ("Ecstasy") induces apoptosis of cultured rat liver cells. Biochim Biophys Acta 1588: 26-32.
  149. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4- methylenedioxymethamphetamine ("Ecstasy"). Eur J Pharmacol 433: 91-99.
  150. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS. (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology. 46: 954-965.
  151. Morgan MJ (1998) Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252-264,
  152. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl) 141: 30-36.
  153. Morgan, MJ, McFie, L, Fleetwood, LH and Robinson, JA (2002). Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology (Berl), 159: 294-303.
  154. Navarro, M, Pichini, S, Farre, M, Ortuno, J, Roset, PN, Segura, J, de la Torre, R (2001). Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: Correlation with plasma drug concentrations and effect of salivary pH. Clinical Chemistry, 47: 1788-1795.
  155. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313.
  156. Nichols DE, Oberlender R. (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann N Y Acad Sci. 1990;600:613-23.
  157. Obergriesser, T, Ende, G, Braus, DF and Henn, FA (2001) Hippocampal 1-HMRSI in ecstasy users. European Archives of Psychiatry and Clinical Neuroscience, 251: 114-116.
  158. Oliveri M, Calvo G (2003) Increased visual cortical excitability in ecstasy users: a transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry. 74:1136- 1138.
  159. O'Regan MC, Clow A (2004) Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology (Berl). 173:446-451. Epub 2004 Jan 30. O'Suilleabhain P, Giller C. (2003) Rapidly progressive parkinsonism in a self-reported user of Ecstasy and other drugs. Mov Disord. 2003 Nov;18(11):1378-1381.
  160. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65:L309-L316.
  161. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Hernandez Lopez C,
  162. Ortuno J, Segura J, Cami J, de la Torre R (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914:215-224.
  163. Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296:207-215.
  164. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965:421-433.
  165. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset P, Segura J, De La Torre R (2004) Paroxetine Inhibits Acute Effects of MDMA on the Immune System in Humans. J Pharmacol Exp Ther 309:285-292.
  166. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition:Saturday night dance. Psychopharmacology (Berl) 139: 261-268.
  167. Peng W, Simantov R. (2003) Altered gene expression in frontal cortex and midbrain of 3,4-methylenedioxymethamphetamine (MDMA) treated mice: differential regulation of GABA transporter subtypes. J Neurosci Res. 2003 Apr 15;72(2):250-258.
  168. Pichini S, Navarro M, Pacifici R, Zuccaro P, Ortuno J, Farre M, Roset PN, Segura J, de la Torre R. (2003) Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J Anal Toxicol. 27:294-303.
  169. Pizarro N, Ortuno J, Farre M, Hernandez-Lopez C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, Cami J, de la Torre R (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26: 157-165.
  170. Pizarro N, Llebaria A, Cano S, Joglar J, Farre M, Segura J, de la Torre R. (2003) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 17: 330-336.
  171. Pompei P, Cavazzuti E, Martarelli D, Pediconi D, Arletti R, Lucas L, Massi M (2002).
  172. Preprotachykinin A gene expression after administration of 3,4- methylenedioxymethamphetamine (Ecstasy). Eur J Pharmacol 450; 245-251.
  173. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367:490-499.
  174. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M. (2004) Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology. 29:982-990.
  175. Reneman L, Booij K, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001A) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869.
  176. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001B) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"): Preliminary findings. Arch Gen Psychiatry 58: 901-906.
  177. Reneman, L, Majoie, CBLM, Schmand, B, van den Brink, W and den Heeten, GJ (2001c). Pre-frontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: Preliminary report. Biological Psychiatry, 50: 550-554.
  178. Reneman L, Booij, J, Lavalaye, J, de Bruin, K, Reitsma, JB, Boudewijn Gunning, W., den Heeten, GJ, van den Brink, W (2002A). Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: A [123I]-Beta-CIT SPECT study - preliminary report. Psychopharmacology (Berl). 159: 335-340.
  179. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff F, Booij J (2002B). The acute and chronic effects of MDMA ("Ecstasy") on cortical 5HT2A receptors in rat and human brain. Neuropsychopharmacology, 26: 387-396.
  180. Reneman L, Majoie CB, Flick H, den Heeten GJ (2002C). Reduced N-acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethamphetamine (Ecstasy) users: preliminary results. AJNR Am J Neuroradiol, 23: 231-237.
  181. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy"). Science 297:2260-2263.
  182. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003) Retraction. Science 301:1479.
  183. Ricaurte GA (2004) Grant Progress Report. Obtained via Freedom of Information Act (FOIA) Request on January 16, 2004. Link: http://www.maps.org/mdma/retraction/foia012804/progress1.hml.
  184. Robledo P, Balerio G, Berrendero F, Maldonado R. (2004) Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 369:338-349.
  185. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology (Berl) 151: 19-24.
  186. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott A. (2001) Differential effects of Ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol 16: 619-625.
  187. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC. (2003) Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study. J Psychopharmacol. 17:389-396.
  188. Roiser JP, Sahakian BJ (2004) Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology (Berl). 173:411-417.
  189. Rothman R, Baumann M (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88.
  190. Saadat KS, Elliott JM, Colado MI, Green AR. (2004) Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology (Berl). 173:452-453. Epub 2003 Dec 09.
  191. Saldana SN, Barker EL. (2004) Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci Lett 354: 209-212.
  192. Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI (2003) Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44: 449-61.
  193. Schenk S, Gittings D, Johnstone M, Daniela E (2003) Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169: 21-27.
  194. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974: 127-133. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R. (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol. 14:1203-1208.
  195. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69.
  196. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Mol Pharmacol 63: 1223-1229.
  197. Simon NG, Mattick RP (2002) The impact of regular Ecstasy use on memory function. Addiction 97: 1523-1529.
  198. Sprague JE, Preston AS, Leifheit M, Woodside B. (2003A) Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiol Behav. 79:281-287.
  199. Sprague JE, Banks ML, Cook VJ, Mills EM. (2003B) Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305: 159-166.
  200. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug. Br J Addict 87: 1161-1172. Stevens S (1997) Speaking the silence: MDMA in a couple dealing with cancer. MAPS Bulletin 7(4):6-10.
  201. Stevens S (1999) MDMA in a couple struggling with cancer: Two years later. MAPS Bulletin 9(3):15-17.
  202. Stevens S (2000) MDMA and a couple struggling with cancer: Sue's final letter. MAPS Bulletin 9(4):31-34.
  203. Stuerenburg HJ, Petersen K, Buhmann C, Rosenkranz M, Baeumer T, Thomasius R. (2003) Plasma amino acids in ecstasy users. Neuroendocrinol Lett 24: 348-349.
  204. Sue YM, Lee YL, Huang JJ (2002) Acute hyponatremia, seizure, and rhabdomyolysis after ecstasy use. J Toxicol Clin Toxicol 40: 931-932.
  205. Sumnall HR, Jerome L, Doblin R, Mithoefer MC (2004) Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450. Psychopharmacology (Berl) 171:229-230
  206. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH (2002) Cognitive Performance of MDMA-Treated Rhesus Monkeys. Sensitivity to Serotonergic Challenge. Neuropsychopharmacology 27: 993-1005.
  207. Taffe MA, Huitron-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, Gold LH. (2003) MDMA exposure alters cognitive and electrophysiological sensitivity to rapid tryptophan depletion in rhesus monkeys. Pharmacol Biochem Behav 76: 141-152.
  208. Tancer ME, Johnson C-E (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65: 97-101.
  209. Tancer M, Johanson C-E (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d-amphetamine and mCPP. Drug and Alcohol Dependence 72: 33-44.
  210. Tancer ME, Johanson C-E, Freedman RR (2003) MDMA elevates core temperature in warm and cold conditions in man. Data presented at the 65th Annual College on Problems of Drug Dependence Conference, June 15, 2003.
  211. Tancer, ME (2003) Personal communication to L Jerome, January 17, 2003).
  212. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96.
  213. Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL, McGregor IS. (2004) Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology. 2004 Apr;29(4):694-704.
  214. Timar J, Gyarmati S, Szabo A, Furst S. (2003) Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav Pharmacol 14:199-206.
  215. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999,55(1-2):105-115.
  216. Traub SJ, Hoffman RS, Nelson LS (2002) The "Ecstasy" hangover: hyponatremia due to 3,4- methylenedioxymethamphetamine. J Urban Health 79: 549-555.
  217. Verbaten MN (2003) Specific memory deficits in ecstasy users? The results of a meta- analysis. Hum Psychopharmacol 18: 281-290.
  218. Verheyden SL, Henry JA, Curran HV.(2003A)Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18:507-517.
  219. Verheyden SL, Maidment R, Curran HV. (2003B) Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol. 17:371-378.
  220. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, De Visser S, Kuijerps M, Pennings EJM, de Bruin D, van de Wijngaart G, Van Gerven JM, Cohen A (2000) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacol 153: 196-202.
  221. Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA- naive healthy volunteers. Neuropsychopharmacology 19: 241-251.
  222. Vollenweider FX, Gamma A, Liechti M, Huber T. (1999) Is a single dose of MDMA harmless? Neuropsychopharmacology 21: 598-600.
  223. Vollenweider FX, Gucker P, Schönbächler R, Kamber E, Vollenweider-Scherpenhuyzen MFI, Schubiger G, Hell D (2000) Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft für psychiatrie, Psychotherapie und Nervenheilkunde].
  224. Vollenweider FX, Jones RT, Baggott MJ (2001) Caveat emptor: Editors beware. Neuropsychopharmacol 24: 461-462. Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M (2002) Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs 2002,34, 2:171-184.
  225. Von Sydow K, Lieb R, Pfister H, Hoffler M, Wittchen H-U (2002). Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomena? Results from a longitudinal community study. Drug and Alcohol Dependence, 66: 147-159.
  226. Vuori E, Henry JA, Ojanpera II, Nieminen R, Savolainen T, Wahlsten P, Jantti M (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98: 365-368.
  227. Wakonigg G, Sturm K, Saria A, Zernig G. (2003) Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure. Pharmacology 69:180-182.
  228. Wareing M, Fisk JE, Murphy PN (2000) Working memory deficits in current and previous users of MDMA, ('ecstasy'). Br J Psychol 91: 181-188.
  229. Wareing M, Murphy PN, Fisk JE (2004) Visuospatial memory impairments in users of MDMA ("Ecstasy") Psychopharmacology (Berl) Epub ahead of print. 173: 391- 397. Weinbroum AA (2003) Importance of early identification of methylenedioxymethamphetamine ('ecstasy') ingestion in victims of motor vehicle accidents. Eur J Emerg Med 10: 19-22.
  230. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV (2003) Developmental 3,4- methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968: 89-101.
  231. Yin Foo Lee G, Wooi Kee Gong G, Vrodos N, Patrick Brophy B. (2003) Ecstasy'- induced subarachnoid haemorrhage: an under-reported neurological complication? J Clin Neurosci. 2003 Nov;10(6):705-707.
  232. Zakzanis KK, Young DA (2001) Memory impairment in abstinent MDMA ("Ecstasy") users: A longitudinal investigation. Neurology 56: 966-969.
  233. Zakzanis KK, Young DA, Radkhoshnoud NF (2002) Attentional processes in abstinent methylenedioxymethamphetamine (Ecstasy) users. Appl Neuropsychol 9: 84-91
  234. Zhou JF, Chen P, Zhou YH, Zhang L, Chen HH (2003A) 3,4- Methylenedioxymethamphetamine (MDMA) Abuse may Cause Oxidative Stress and Potential Free Radical Damage. Free Radical Research, 37: 491-497.
  235. Zhou JF, Zhou YH, Zhang L, Chen HH, Cai D (2003B) 3,4- methylenedioxymethamphetamine (MDMA) abuse markedly inhibits acetylcholinesterase activity and induces severe oxidative damage and liperoxidative damage. Biomed Environ Sci 16: 53-61.